Oxford Asset Management’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Oxford Asset Management’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-35,247	Closed	-$455K	–	1483
2019 Q4	$455K	Buy	35,247 +5,612	+19%	+$51.8K	0.01%	1279
2019 Q3	$311K	Sell	29,635 -18,398	-38%	-$240K	0.01%	1443
2019 Q2	$817K	Buy	48,033 +12,360	+35%	+$335K	0.02%	1070
2019 Q1	$1.2M	Buy	35,673 +25,176	+240%	+$841K	0.03%	838
2018 Q4	$307K	Buy	+10,497	New	+$466K	0.01%	1397

Other funds holding BLCM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Oxford Asset Management's BLCM Position: Q1 2020 in Review

Oxford Asset Management sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q1 2020, closing a stake of 35,247 shares — an estimated $455K sold.

Oxford Asset Management first reported a position in BLCM in Q4 2018 and held it in 5 quarters. The position peaked at $1.2M in Q1 2019. 29 funds tracked by Wall St. Rank hold BLCM as of Q1 2020.

Oxford Asset Management reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
Oxford Asset Management sold 35,247 Bellicum Pharmaceuticals, Inc. shares in Q1 2020, an estimated $455K.
Oxford Asset Management first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2018 and held it in 5 quarters.
Oxford Asset Management's Bellicum Pharmaceuticals, Inc. position peaked at $1.2M in Q1 2019.
29 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.